Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BTBioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAI)

NASDAQ Capital Market · Currency in USD
$0.07 ▲ +0.03 (+64.22%)
At close: Sep 4, 4:00 PM ET. Market closed.
$0.04 ▼ -0.03 (-43.03%)
After hours: Sep 4, 7:59 PM ET

Summary

Previous Close
$0.05
Open
$0.09
Day's Range
$0.07 – $0.09
52 Week Range
$0.02 – $2.87
Volume
47,480,718
Avg. Volume
2,356,355
Market Cap
$2.28M
Beta (5Y Monthly)
0.29
PE Ratio (TTM)
--
EPS (TTM)
-$5.80
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$12.00

Profile: BioXcel Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
29
CEO
Vimal D. Mehta

BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$1.01 · Revenue est. $191.39K
DateEst.Actual
Aug 13, 2026-$0.44-$0.49Miss
May 15, 2026-$0.59-$0.54Beat
Mar 26, 2026-$0.34-$0.58Miss
Nov 12, 2025-$1.54-$2.18Miss
Aug 12, 2025-$2.30-$2.45Miss
May 12, 2025-$2.72-$1.50Beat

Analyst view

Consensus price target
$12.00 ▲ +16,138.2%
Range $1.00 – $25.00
Rating: Buy
Buy 53% · Hold 40% · Sell 7%

Get free alerts on BTAI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.